Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer

Former AstraZeneca CMO Sean Bohen Helms The Phase I Firm

Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.

Finance Watch

Olema Pharmaceuticals, Inc. is not hurting for money after raising $139m in venture capital so far in 2020, but the company went public in the US on 18 November anyway to speed up clinical development of lead drug candidate OPI-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) undergoing a Phase I/II clinical trial in patients with estrogen receptor-positive (ER+)/HER2-negative locally advanced or metastatic breast cancer.

San Francisco-based Olema, also known as Olema Oncology, brought in $209m from the sale of 11 million shares at $19...

More from Financing

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.